The novel anthraquinone compound Kanglexin (KLX) has been investigated for its potential to prevent EndMT in atherosclerosis by targeting the fibroblast growth factor receptor 1 (FGFR1 ...
Hosted on MSN1mon
KLX mitigates atherosclerotic progression by preventing EndMTThe novel anthraquinone compound Kanglexin (KLX) has been investigated for its potential to prevent EndMT in atherosclerosis by targeting the fibroblast growth factor receptor 1 (FGFR1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback